Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for cancer. Its lead product candidate is Revuforj (revumenib), a menin inhibitor for treating relapsed or refractory acute leukemia. The company also markets Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody for chronic graft-versus-host disease. Additionally, Syndax is developing revumenib for acute myeloid leukemia with an mNPM1 mutation and in combination therapies for other leukemias, as well as for metastatic colorectal cancer. Its pipeline includes axatilimab for idiopathic pulmonary fibrosis and Entinostat, a Class 1 HDAC inhibitor. The company was incorporated in 2005 and is headquartered in New York, New York.

Syndax Pharmaceuticals, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SNDX. Trading is conducted in US Dollars (USD), which is the company's reporting currency. As a US-based company listed on a major American exchange, its shares are primarily traded by investors in the United States and internationally.

Syndax Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on researching, developing, and commercializing therapies for cancer. Biotechnology companies like Syndax use biological processes and living organisms to create drugs, distinguishing them from traditional pharmaceutical companies that often rely on chemical synthesis. The company's work in oncology places it at the forefront of innovative cancer treatments.

Syndax Pharmaceuticals is headquartered in New York, New York, United States. The company serves the US market primarily, as indicated by its US-based operations and listing on the Nasdaq exchange. While its therapies target global health issues like cancer, its commercial activities and partnerships are centered in the United States. Notably, Syndax has an agreement with Eddingpharm International Company Limited for the licensing, development, and commercialization of Entinostat, which may extend its reach to other regions.

Syndax Pharmaceuticals' main products include Revuforj (revumenib), a menin inhibitor approved for relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody for chronic graft-versus-host disease. The company is also developing revumenib for acute myeloid leukemia with an mNPM1 mutation and in combination therapies for other leukemias and metastatic colorectal cancer. Additionally, its pipeline features axatilimab for idiopathic pulmonary fibrosis and Entinostat, a Class 1 HDAC inhibitor licensed to Eddingpharm. These products target significant unmet medical needs in oncology and inflammatory diseases.